Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Chinese Company Develops New Drug to Fight HIV/AIDS

July 11, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

A Chinese pharmaceutical maker has developed a new HIV drug that aims to block the virus from entering cells, the China Daily reported today. FusoGen Pharmaceuticals is currently testing the drug, a fusion inhibitor, in clinical trials. Zhou Genfa, FusoGen's chairperson, said the drug is modeled after the U.S.-developed Fuzeon -- the first drug in a new class of fusion inhibitors -- but employs a different molecular modeling. The drug, which has been registered as a new medicine with China's State Food and Drug Administration, will likely hit the market at the end of next year and will be priced "significantly" lower than Fuzeon, which can cost $20,000 per patient per year, said Zhou.

Back to other news for July 11, 2005

Adapted from:
Agence France Presse
07.11.05

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More on HIV Medications
More News on T-20 (Enfuvirtide, Fuzeon)

Tools
 

Advertisement